UNSPSC 51322405: Terbufibrol

This classification denotes an anti-lipidemic agent with the molecular formula C20H24O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W41Z308IA3, chemically known as 4-(3-(4-(1,1-dimethylethyl)phenoxy)-2-hydroxypropoxy)benzoic acid but generally known as terbufibrol, which bears US NIH Compound Identifier 41907. European Medicines Agency schedules Terbufibrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10912MIG.

UNSPSC 51322405 Terbufibrol is a Commodity code representing pharmaceuticals and active pharmaceutical ingredients procured by state and local health agencies, primarily emergency medical services and pharmacy benefit programs. State and local governments buy emergency medications, generic pharmaceuticals, and over-the-counter products under this code, as evidenced by recent solicitations targeting specific drug formulations for EMS protocols, wholesale pharmaceutical supply agreements, and state pharmacy benefit expansion initiatives. Issuing bodies include municipal fire and rescue departments, state health and human services commissions, and multi-state cooperative purchasing alliances. The City of Tampa's Fire Rescue division and the Texas Health and Human Services Commission represent typical customers; cooperative purchasing mechanisms like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) consolidate procurement across multiple member jurisdictions and states, creating larger aggregated opportunities than single-jurisdiction buys.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa issued IFB No. 26P00188 in April 2026 for Advanced Life Support Medications (labetalol, epinephrine, adenosine, and diltiazem vials) with a due date of April 8, 2026 and estimated contract value of $40,000.00, with a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI No. HHS0017013 in early April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, signaling exploratory procurement before formal RFP issuance. MMCAP issued RFP No. S1070000015802 for generic multi-source pharmaceuticals and OTC products across participating states, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026; this procurement requires vendors to maintain relationships with three authorized wholesalers and comply with cGMP and DSCSA standards, with price competitiveness weighted at 75 percent of the evaluation.